Skip to main content
OpenTrials
Completed

NCT Number: NCT07267728

A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

This is a single-group, virtual clinical trial evaluating the effects of a daily dietary supplement (DITTO Cycle Supplement) on menstrual cycle symptoms across three menstrual cycles. The study investigates changes in symptom severity and quality of life through validated questionnaires including the Menstrual Symptoms Questionnaire (MSQ).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Premenstrual Syndrome Dysmenorrhea Menstrual Pain Menstruation Disturbances Mental Disorders Mood Disorders Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Pelvic Pain Signs and Symptoms

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female-at-birth
  • Aged 18-45
  • In the last three menstrual cycles, has experienced three or more of the following symptoms associated with their menstrual cycle: Menstrual cramps, Bloating, Breast tenderness, Headaches, Fatigue, Muscle aches and/or joint pain, Cravings, Mood swings, Low mood, Feelings of anxiety, Irritability, Difficulty concentrating
  • Generally healthy - does not live with any uncontrolled chronic disease
  • Has a regular menstrual cycle length, between 23 and 35 days
  • Tracks their menstrual cycle and can predict their period dates
  • Anyone willing to comply with study requirements
  • Anyone with no known allergies to the ingredients listed in the product

Exclusion criteria

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
  • Women who are pregnant, breastfeeding, or trying to conceive
  • Anyone unwilling to follow the study protocol
  • Anyone in perimenopause, menopause, or experiencing menopausal-type symptoms
  • Anyone with planned surgery during the study period
  • Anyone with a history of substance abuse
  • Anyone diagnosed with high blood pressure, high cholesterol, heart disease, heart attack, stroke, irregular heartbeat (AFib), clogged arteries, poor circulation, heart failure, or other heart conditions
  • Anyone diagnosed with a hormone or reproductive health-related cancer or benign condition
  • Anyone diagnosed with a menstrual health condition such as endometriosis, PCOS, or adenomyosis
  • Anyone diagnosed with diabetes or other endocrine-related condition
  • Anyone currently participating or planning to participate in a research study
  • Anyone who has started, changed, or stopped taking hormonal birth control in the last three months
  • Has a planned insertion or replacement of an IUD in the next 12 weeks

Treatment and study plan

DITTO Cycle Supplement

Dietary Supplement

The capsules should be taken in the morning with the first meal and a glass of water.

Primary outcomes

  1. Change in Menstrual Symptoms Questionnaire (MSQ) Scores

    Time frame: Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

    Change from baseline in menstrual symptom severity as measured by the Menstrual Symptoms Questionnaire (MSQ), including cramps, bloating, fatigue, mood swings, breast tenderness, headaches, anxiety, irritability, and difficulty concentrating.

Secondary outcomes

  1. Change in Menstrual-Related Quality of Life

    Time frame: Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

    Change from baseline in participant-reported quality of life related to menstrual symptoms, measured using study-specific self-report questionnaires evaluating overall impact on daily living and well-being.

Sponsors and collaborators

Lead sponsor

Muse Nutrition Ltd

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 5, 2025
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.